DRG Market Assessment reports

China accounts for approximately half of the gastroesophageal cancer cases (including gastric, gastroesophageal junction, and esophageal cancer) in the world. Standard-of-care (SOC) treatments…

Asthma is a common chronic airway disease that affects children and adults. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair /…

Asthma is a common chronic airway disease that affects children and adults. The asthma therapy market in China consists of many well-established agents, including inhaled agents (GSK’s Advair /…

Market outlook Alzheimer’s disease (AD) is a progressive and irreversible brain disorder that leads to a decline in cognitive abilities, affecting memory and causing patients’ quality of life…

Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…

Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…

Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…

Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the…

Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-…

Bladder cancer is the eighth most diagnosed kind of cancer in China. The bladder cancer therapy market will experience rapid growth over the forecast period, fueled by one of the most robust drug-…

CAR T-cell therapy is a novel approach to cancer adoptive immunotherapy. The ongoing regulatory reforms, such as the breakthrough therapy designation (BTD) and priority review pathway, have…

China’s biosimilar market has evolved rapidly over the past four years since the approval of Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab)—in February 2019. As of 2022…